Skip Navigation



Alcohol and Alcoholism Advance Access published online on May 21, 2008
Alcohol and Alcoholism, doi:10.1093/alcalc/agn043
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/4/456    most recent
agn043v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Aliyev, Z. N.
Right arrow Articles by Aliyev, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aliyev, Z. N.
Right arrow Articles by Aliyev, N. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the Medical Council on Alcohol 2008

Valproate Treatment of Acute Alcohol Hallucinosis: A Double-Blind, Placebo-Controlled Study

Zafar N. Aliyev1 and Nadir A. Aliyev2,*

1 Narcological Dispensary of Ministry of Health of Azerbaijan Republic, Azerbaijan Republic
2 Dispensary of Mental Hygiene, U. Chagibekov Street, 46/50 F. 1, Baku PO Az0010, Azerbaijan Republic

* Corresponding author: Dispensary of Mental Hygiene, U. Chagibekov Street, 46/50, F. 1, Baku PO Az0010, Azerbaijan Republic. E-mail: aliyevnadir{at}yahoo.com

Received 27 May 2007; first review notified 27 July 2007; in revised form 8 October 2007; accepted 25 April 2008


  Abstract

Aims: The aim of this study was to compare the efficacy and safety of valproate (Depakine-Chrono) versus placebo for the treatment of acute alcohol hallucinosis. Methods: 10 days’ randomized, double-blind, parallel study was conducted; 40 patients with an ICD-10 diagnosis of acute alcohol hallucinosis were randomized to valproate (Depakine-Chrono) 3000 mg/day (n = 20) or placebo (n = 20). The primary efficacy measure was the Clinical Global Improvement (CGI) and the Positive and Negative Syndrome Scale (PANSS), subscale for hallucinosis. Results: Valproate-treated patients demonstrated a greater improvement than placebo-treated patients in CGI (P < 0.001) and PANSS subscale for verbal hallucinosis (P < 0.001). Conclusion: Valproate is effective in the treatment of acute hallucinosis and is generally well tolerated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Alcohol AlcoholHome page
M. Soyka
Pharmacological Treatment of Alcohol Hallucinosis
Alcohol Alcohol., November 1, 2008; 43(6): 719 - 720.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.